Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

Breast

Volumn 20, Issue 2, 2011, Pages 176-183

  Zambelli, Alberto ^a   Della Porta, Matteo Giovanni ^a   Eleuteri, Ermanno ^a   De Giuli, Luciana ^a   Catalano, Oronzo ^a   Tondini, Carlo ^b   Riccardi, Alberto ^a  

^a IRCCS   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Breast cancer; Cardiotoxicity; Molecular medicine; Targeted therapy

Indexed keywords

ADRENOMEDULLIN; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOTHELIAL PROGENITOR CELL; GASTROINTESTINAL STROMAL TUMOR; GENETIC RISK; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VEIN THROMBOSIS;

EID: 79952622679     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.11.002     Document Type: Article

References (98)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
2. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
3. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
4. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
5. Fromme E.K., Eilers K.M., Mori M., Hsieh Y.C., Beer T.M. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22:3485-3490.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
7. Wysocki P.J., Wysocki H. Cardiovascular complications associated with biological therapies for breast cancer. Expert Opin Biol Ther 2008, 8(10):1551-1559.
8. Mann D.L. Targeted cancer therapeutics: the heartbreak of success. Nat Med 2006, 12(8):881-882.
9. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008, 8(4):324-333.
10. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221.
11. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23(31):7820-7826.
12. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
13. Pentassuglia L., Graf M., Lane H., Kuramochi Y., Cote G., Timolati F., et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res. 2009, 315(7):1302-1312.
14. Schneider J.W., Chang A.Y., Rocco T.P. Cardiotoxicity signal transduction therapeutics erbB antibodies heart. Semin Oncol 2001, 28(5 Suppl. 16):18-26.
15. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002 May, 8(5):459-465.
16. Meyer D., Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995, 378:386-390.
17. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hübner N., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002 Jun 25, 99(13):8880-8885.
18. Halyard M.Y., Pisansky T.M., Dueck A.C., Suman V., Pierce L., Solin L., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009 Jun 1, 27(16):2638-2644.
19. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006 Dec 28, 355(26):2733-2743.
20. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83(6):679-686.
21. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004 Sep 1, 10(17):5650-5655.
22. Spector N.L., Yarden Y., Smith B., Lyass L., Trusk P., Pry K., et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A 2007 Jun 19, 104(25):10607-10612.
23. Cohen M.H., Gootenberg J., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12(6):713-718.
24. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3, 350(23):2335-2342.
25. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31, 349(5):427-434.
26. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb 1, 23(4):792-799.
27. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27, 357(26):2666-2676.
28. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl. 16):117-124.
29. Hurwitz H., Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006, 33(5 Suppl. 10):26-34.
30. Vaklavas C., Lenihan D., Kurzrock R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 2010, 15(2):130-141.
31. Stone R.L. Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010, 11(5):465-475.
32. Eskens F., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006, 42:3127-3139.
33. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(12):1788-1795.
34. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28(13):2280-2285.
35. Force T., Kerkela R. Cardiotoxicity of the new cancer therapeutics-mechanism of, and approaches to, the problem. Drug Discov Today 2008, 13(17-18):778-784.
36. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocite survival in response to pressure overload. Circulation 2004, 110:718-723.
37. Wu S., Chen J.J., Kudelka A., Lu J., Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 2:117-123.
38. Muslin A.J. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 2005, 15(6):225-229.
39. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006 Oct 14, 368(9544):1329-1338.
40. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19(9):1613-1618.
41. Kerkela R., Woulfe K.C., Durand J.B., Vagnozzi R., Kramer D., Chu T.F., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009 Feb, 2(1):15-25.
42. Altena R., Perik P.J., van Veldhuisen D.J., de Vries E.G., Gietema J.A. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009, 10(4):391-399.
43. Biomarkers Definitions Working Group. Biomarkers and surrogate endopoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
44. Braunwald E. Biomarkers in heart failure. N Eng J Med 2008, 358:2148-2159.
45. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004 Jun 8, 109(22):2749-2754.
46. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998 Aug, 136(2):362-363.
47. Cardinale D., Colombo A., Torrisi R., Sandri M.T., Civelli M., Salvatici M., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010 Sep 1, 28(25):3910-3916.
48. Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006 Dec 5, 114(23):2474-2481.
49. Bryant J., Picot J., Baxter L., Levitt G., Sullivan I., Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007 Sep, 43(13):1959-1966.
50. Kakkar R., Lee R.T. ST2 and adrenomedullin in heart failure. Heart Failure Clin 2009, 5:515-527.
51. Zambelli A., Della Porta M.D., Rosti V. From cancer patients to cancer survivors: the issue of Cardioncology. A biological perspective. Eur J Cancer 2010 Mar, 46(4):697-702.
52. Chen M.H., Kerkela R., Force T. Mechanism of cardiac dysfunction associated with tyrosin kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
53. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26:3777-3784.
54. Von Haehling S., Schefold J.C., LainscaK M., Doehner W., Anker S. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Failure Clin 2009, 5:549-560.
55. Niessner A., Hohensinner P.J., Rychli K., Neuhold S., Zorn G., Richter B., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009 Apr, 30(7):789-796.
56. Perik P.J., de Vries E.G., Gietema J.A., van der Graaf W.T., Smilde T.D., Sleijfer D.T., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail. 2007 Feb, 9(2):173-177.
57. Urbich C., Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004, 95:343-353.
58. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 Feb 14, 275(5302):964-967.
59. Heil M., Eitenmuller I., Schmitz-Rixen T., Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006, 10:45-55.
60. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003 Feb 13, 348(7):593-600.
61. Mancuso P., Antoniotti P., Quarna J., Calleri A., Rabascio C., Tacchetti C., et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res. 2009 Jan 1, 15(1):267-273.
62. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 Sep 8, 353(10):999-1007.
63. Kunz G.A., Liang G., Cuculi F., Gregg D., Vata K.C., Shaw L.K., et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006 Jul, 152(1):190-195.
64. Massa M., Rosti V., Ferrario M., Campanelli R., Ramajoli I., Rosso R., et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005 Jan 1, 105(1):199-206.
65. Leone A.M., Rutella S., Bonanno G., Abbate A., Rebuzzi A.G., Giovannini S., et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005 Jun, 26(12):1196-1204.
66. Cardinale D., Colombo A., Cipolla C.M. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 2008 Dec, 10(6):486-495.
67. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American heart association Task Force on Practice guidelines (Writing Committee to Update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of chest Physicians and the International Society for heart and lung Transplantation: endorsed by the heart Rhythm Society. Circulation 2005; 112: 154-235.
68. Dobrucki L.W., Sinusas A.J. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010 Jan, 7(1):38-47.
69. Jannazzo A., Hoffman J., Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 2008, 42:99-104.
70. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26:1201-1203.
71. Nousiainen T., Jantunen E., Vanninen E., et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002, 86:1697-1700.
72. Wang J., Khoury D.S., Thohan V., Torre-Amione G., Nagueh S.F. Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures. Circulation 2007 Mar 20, 115(11):1376-1383.
73. Tassan-Mangina S., Codorean D., Metivier M., Costa B., Himberlin C., Jouannaud C., et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006 Mar, 7(2):141-146.
74. Nakamae H., Tsumura K., Hino M., Hayashi T., Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000 Mar 4, 355(9206):805-806.
75. Zhang X., Liu X.J., Wu Q., Shi R., Gao R., Liu Y., et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med 2001 Aug, 42(8):1166-1173.
76. Verani M.S., Taillefer R., Iskandrian A.E., Mahmarian J.J., He Z.X., Orlandi C. 123I-IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid. J Nuc Med 2000, 41:1299-1307.
77. Wagner B., Anton M., Nekolla S.G., Reder S., Henke J., Seidl S., et al. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. J Am Coll Cardiol 2006 Nov 21, 48(10):2107-2115.
78. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998, 4:623-626.
79. Shi C.Q., Young L.H., Daher E., DiBella E.V., Liu Y.H., Heller E.N., et al. Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. J Nucl Med 2002 Mar, 43(3):421-431.
80. Higuchib T., Schwaiger M. Noninvasive imaging of heart failure: neuronal dysfunction and risk stratification. Heart Fail Clin 2006, 2:193-204.
81. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
82. Brack S.S., Dinkelborg L.M., Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging 2004, 31:1327-1341.
83. Lu E., Wagner W.R., Schellenberger U., Abraham J.A., Klibanov A.L., Woulfe S.R., et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003 Jul 8, 108(1):97-103.
84. Deng S., Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc. Toxicol 2007, 7:129-134.
85. Han W., Kang D., Lee J.E., Park I.A., Choi J.Y., Lee K.M., et al. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res. 2005 Jul 1, 11(13):4775-4778.
86. Beauclair S., Formento P., Fischel J.L., Lescaut W., Largillier R., Chamorey E., et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007 Aug, 18(8):1335-1341.
87. Rajasekaran R., George Priya Doss C., Sudandiradoss C., Ramanathan K., Purohit R., Sethumadhavan R. Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C.R.Biologies 2008, 331(6):409-417.
88. Alexeyev M.F., LeDoux S.P., Wilson G.L. Mitochondrial DNA and aging. Clin Sci 2004, 107(4):355-364.
89. Lebrecht D. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):108-113.
90. Meister G., Tuschl T. Mechanisms of gene silencing by doublestranded RNA. Nature 2004, 431(7006):343-349.
91. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006 Nov 28, 103(48):18255-18260.
92. Tan-Chiu E., Yothers G., Romond E., Geyer C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005 Nov 1, 23(31):7811-7819.
93. Russell S.D., Blackwell K.L., Lawrence J., Pippen J.E., Roe M.T., Wood F., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010 Jul 20, 28(21):3416-3421.
94. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 Feb 23, 354(8):809-820.
95. Chia S., Clemons M., Martin L.A., Rodgers A., Gelmon K., Pond G.R., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006 Jun 20, 24(18):2773-2778.
96. Costa R.B., Kurra G., Greenberg L., Geyer C.E. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010 Mar 29, (Epub ahead of print).
97. Gennari A., Pronzato P. New Uunderstanding role anthracyclines early-stage breast cancerof the role of anthracyclines in early-stage breast cancer: Patient Selection Considerations. Clin Breast Cancer 2008, 8(Suppl 4):S179-S183.
98. Di Leo A., Biganzoli L., Claudino W., Licitra S., Pestrin M., Larsimont D. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?. Eur J Cancer 2008 Dec, 44(18):2791-2798.